More Efficient, Evidence-Based PA Process Could Benefit Genomic Testing
-
Jul 13, 2023
With more than 77,000 genetic tests available and new tests constantly coming to market, it can be difficult for payers and providers alike to keep track of not just what the products are but also how effective they can be. To make sure that beneficiaries are receiving appropriate testing, many payers have prior authorization (PA) in place. But as the process often can be burdensome for providers, a more evidence-based, streamlined approach to coverage could authorize necessary genomic testing with greater efficiency.
AHIP conducted a study from February through April 2022 on PA practices and received responses from 26 health plans with 122 million commercial covered lives. Along with specialty drugs, genetic testing was the only other treatment that respondents said was subject to PA 100% of the time.
Read more
© 2024 MMIT
Related Posts
-
![]()
Apr 13
People Are Seeing Benefits From Biomarker Testing, but Barriers to Coverage Remain
Read more -
![]()
Dec 08
Collaboration Is Needed Among Stakeholders for Genetic Tests to Be Beneficial
Read more -
![]()
Dec 08
Study Shows Only About One-Third of People With NSCLC Are Benefiting From Appropriate Care
Read more
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.